Bedrijfsoverzicht
CASI Pharmaceuticals, Inc. is a biopharmaceutical entity dedicated to the development and commercialization of therapeutics and pharmaceutical products across the People's Republic of China, the United States, and international markets. The company operates within the healthcare sector, specifically the biotechnology industry, where it focuses on creating specialized treatments such as EVOMELA, an intravenous formulation of melphalan intended for use as a conditioning treatment prior to stem cell transplantation. The scale of the organization is currently defined by a market capitalization of $11.85M, an annual revenue of $26.85M, and an employee base of 233 individuals. These financial metrics indicate that the company functions as a small-cap entity with limited market penetration, operating with a revenue stream that is significantly smaller than established large-cap peers, which is typical for early-stage biotechnology firms still navigating the complex regulatory and commercialization pathways required to bring novel therapies to market.
Financiële gezondheid
The company reported a revenue of $26.85M over the trailing twelve months, yet this figure masks a substantial operational deficit, as the net income for the same period was -$49,385,000, while EBITDA stood at -$42,272,500. The significant disparity between the positive revenue of $26.85M and the negative net income reveals a cost structure characterized by high operating expenses relative to sales, which is common in the biotech sector but indicates that current commercial activities are not yet covering the costs of research, development, and general administration. Regarding liquidity and flexibility, the company holds $4.68M in cash, yet free cash flow is listed as N/A, suggesting that the company is currently burning through its cash reserves to fund operations rather than generating excess cash for reinvestment or shareholder returns. The margin analysis highlights severe profitability challenges, with a gross margin of 35.8%, an operating margin of -333.1%, and a profit margin of -184.0%, indicating that for every dollar of revenue, the company loses significantly more than a dollar in operating costs and overall profit. The balance sheet presents a leveraged position, as the total debt of $18.86M exceeds the cash on hand of $4.68M, and the debt-to-equity ratio is listed as N/A, implying that equity levels are either zero or insufficient to calculate a standard ratio, which increases financial risk. Short-term liquidity is constrained by a current ratio of 0.30, meaning the company possesses only 30 cents in current assets for every dollar of current liabilities, signaling potential difficulties in meeting immediate obligations without additional financing. Finally, the return metrics show a return on equity of N/A and a return on assets of -61.8%, revealing that management is currently unable to generate positive returns on the capital invested, reflecting the high-risk nature of the business model where assets are consumed to develop products that have not yet generated sufficient commercial revenue.
Waarderingsbeoordeling
Valuation multiples for CASI reflect its lack of profitability, as the P/E Ratio (TTM) is N/A and the forward P/E is -0.36, a negative figure that implies expected earnings are anticipated to remain negative in the near term rather than indicating a discount to book value. The price-to-book ratio stands at -0.55, which indicates that the market is pricing the company at less than half of its book value, a situation often seen in biotech firms with significant intangible assets that are not fully captured on the balance sheet or where the book value does not reflect the potential value of the pipeline. Alternative valuation metrics provide further insight into the market's skepticism regarding future cash generation, with a price-to-sales ratio of 0.44 and an EV/EBITDA of -0.71, suggesting that the market is valuing the company primarily on its revenue potential rather than its earnings power. Price action analysis shows a 52-week high of $3.09 and a 52-week low of $0.74, placing the current share price in a highly volatile range where the stock trades well below its recent peak but remains above its yearly minimum, reflecting the speculative nature of the investment. The beta value of 0.89 indicates that the stock's price volatility is slightly lower than the broader market, suggesting that while the asset is still subject to significant market movements, it does not exhibit the extreme leverage or momentum often associated with small-cap biotechnology stocks.
Growth & Income
The company's growth trajectory is characterized by a contraction in financial performance, with revenue growth year-over-year declining by -60.5% and earnings growth year-over-year listed as N/A due to the negative earnings base. This negative revenue growth implies that the company is either reducing its commercial footprint, facing headwinds in specific markets, or transitioning its business model, as there is no positive earnings growth to offset the decline in sales volume. As a non-dividend payer, the company distributes no cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm prioritizes retaining any available capital for research and development rather than providing income to investors. Consequently, the overall growth and income profile of CASI is defined by significant revenue contraction and a complete absence of dividend income, reflecting a high-risk, high-reward strategy typical of biotechnology firms that rely on future product approvals and commercial success to achieve long-term viability.